<DOC>
	<DOCNO>NCT02416765</DOCNO>
	<brief_summary>Postprandial meal glucose control closed-loop system ( CLS ) still need improvement . In postprandial period , sensor delay detect blood glucose rise meal together delay insulin absorption expose patient early risk hyperglycemia late-postprandial hypoglycemia . Glucagon infusion dual-hormone CLS potential improve post-meal control compare single-hormone CLS allow well glucose excursion relate aggressive insulin infusion minimize hypoglycemic risk . Several approach test determination prandial boluses closed-loop operation . The objective study test outpatient unrestricted setting whether , context closed-loop strategy , conventional meal carbohydrate counting could reduce simplified qualitative meal size estimation without significant degradation overall glycemic control adult patient type 1 diabetes . The investigator hypothesize outpatient free-living condition : 1 ) Dual-hormone CLS partial bolus equivalent dual-hormone CLS full bolus term mean glucose ; 2 ) Single-hormone CLS partial bolus equivalent single-hormone CLS full bolus term mean glucose . Secondary hypothesis : 3 ) Dual-hormone CLS partial bolus decrease time hypoglycemia compare single-hormone CLS partial bolus ; 4 ) Dual-hormone CLS partial bolus well sensor-augmented pump therapy term mean glucose ; 5 ) Single-hormone CLS partial bolus well sensor-augmented pump therapy term mean glucose .</brief_summary>
	<brief_title>Closed-loop Control Postprandial Glucose Levels Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Males females ≥ 18 year old . 2 . Clinical diagnosis type 1 diabetes least one year . 3 . The subject insulin pump therapy least 3 month currently use fast actin insulin analog ( Lispro , Aspart Guilisine ) . 4 . Last ( less 3 month ) HbA1c ≤ 10 % . 5 . Currently use carbohydrate counting meal insulin dose strategy . 1 . Clinically significant microvascular complication : nephropathy ( estimate glomerular filtration rate 40 ml/min ) , neuropathy ( especially diagnose gastroparesis ) severe proliferative retinopathy judge investigator . 2 . Recent ( &lt; 3 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . 3 . Ongoing pregnancy . 4 . Severe hypoglycemic episode within 1 month screening . 5 . Agents affect gastric emptying ( Motilium® , Prandase® , Victoza® , Byetta® Symlin® ) well oral antidiabetic agent ( Metformin , SGLT2 inhibitor DPP4 inhibitor ) stable dose 3 month . Otherwise , medication acceptable keep stable entire protocol . 6 . Oral steroid unless patient present low stable dose ( e.g . 10 mg less prednisone per day physiological dos , less 35 mg/day , hydrocortisone Cortef® ) . Inhale steroid stable dose last month acceptable . 7 . Other serious medical illness likely interfere study participation ability complete trial judgment investigator ( e.g . unstable psychiatric condition ) . 8 . Failure comply team 's recommendation ( e.g . willing change pump parameter , follow algorithm 's suggestion , etc ) . 9 . Living plan travel outside Montreal ( &gt; 1h drive ) area closedloop procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Closed-loop strategy</keyword>
	<keyword>Artificial pancreas</keyword>
	<keyword>Postprandial glucose</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Type 1 diabetes</keyword>
</DOC>